SCHEMBL3761829

SCHEMBL3761829

COC(=O)c1ccc(O)c(O)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.53
CA1 P00915 4/20 0.53
CA2 P00918 4/20 0.53
CA7 P43166 4/20 0.53
CA9 Q16790 4/20 0.53
CA14 Q9ULX7 4/20 0.53
PDK2 Q15119 1/20 0.53
PDK4 Q16654 1/20 0.53
LMNA P02545 3/20 0.52
TSHR P16473 1/20 0.52
GAA P10253 3/20 0.50
MYC P01106 1/20 0.47
KDM4E B2RXH2 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
XDH P47989 2/20 0.46
LCK P06239 1/20 0.45
MAPT P10636 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466430 1.00 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL733030 0.86 CA1 (0.55) CA12CA1CA2CA7CA9
SCHEMBL2590792 0.84 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL5589044 0.84 MEN1 (0.43) CA12CA1CA2CA7CA9
SCHEMBL947039 0.83 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL31473107 0.83 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL3422644 0.83 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL25343413 0.82 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL12553221 0.82 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL13117418 0.81 TSHR (0.50) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117567280-A Preparation method of 3, 4-dihydroxy-2-methyl benzoate 浙江瑞博制药有限公司 2024-02-20 CN claimed
CN-105130808-B Synthesis method of high-purity 2, 5-dimethyl-3, 4-dihydroxy methyl benzoate 上海瑞博化学有限公司 2020-05-19 CN claimed
US-12612390-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-12516040-B2 Crystalline forms of 7-chloro-2-(4-3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide CONSTELLATION PHARMACEUTICALS, INC. (US) 2026-01-06 US disclosed
US-20250320222-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED LTD (CN) 2025-10-16 US disclosed
US-12344618-B2 Heterotricyclic derivative compound and use of same HANMI PHARMACEUTICAL CO., LTD. (KR) 2025-07-01 US disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
WO-2025124531-A1 1, 3-BENZODIOXOL DERIVATIVES AND USES THEREOF GEWU BIO CO., LTD (CN) 2025-06-19 WO disclosed
CN-116194108-B Novel dioxoisoquinolinone derivatives and use thereof 韩美药品株式会社 2025-05-30 CN disclosed
EP-4556479-A1 NOVEL DIOXOLOISOQUINOLINONE DERIVATIVES AND USE THEREOF Hanmi Pharmaceutical Co., Ltd. (KR) 2025-05-21 EP disclosed
CN-119954787-A Modulators of methyl-modified enzymes, compositions and uses thereof 星座制药公司 2025-05-09 CN disclosed
US-20080103113-A1 Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand HORMANN ROBERT E 2008-05-01 US disclosed
US-20080103113-A1 Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand HORMANN ROBERT E 2008-05-01 US disclosed
US-20080103113-A1 Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand HORMANN ROBERT E 2008-05-01 US disclosed
US-7304161-B2 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide INTREXON CORPORATION (US) 2007-12-04 US disclosed
US-7304161-B2 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide INTREXON CORPORATION (US) 2007-12-04 US disclosed
US-7304161-B2 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide INTREXON CORPORATION (US) 2007-12-04 US disclosed
EP-1603860-A2 DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX RheoGene Holdings Inc. (US) 2005-12-14 EP disclosed
US-20050209283-A1 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide ROHM AND HAAS COMPANY 2005-09-22 US disclosed
WO-2004072254-A2 DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE HOLDINGS, INC (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320222-A1 TRICYCLIC COMPOUNDS AND USES THEREOF CYP11B2, CYP11B1, CYP3A7 CA12 485/4885CA1 952/4885CA2 1077/4885
US-20080103113-A1 Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand NR5A1, NR0B2, NR0B1 CA12 3983/4885CA1 3685/4885CA2 4052/4885
US-12344618-B2 Heterotricyclic derivative compound and use of same EZH2, EZH1, BMI1 CA12 2957/4885CA1 3124/4885CA2 1595/4885
US-12612390-B2 Modulators of methyl modifying enzymes, compositions and uses thereof NSD1, DOT1L, EHMT2 CA12 2101/4885CA1 3143/4885CA2 2251/4885
US-20050209283-A1 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide NR5A2, NR2C2, NR0B2 CA12 4213/4885CA1 3722/4885CA2 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.